Akers Biosciences (NASDAQ:AKER) and Quotient (NASDAQ:QTNT) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, dividends and profitability.
This is a breakdown of recent ratings for Akers Biosciences and Quotient, as provided by MarketBeat.
Quotient has a consensus price target of $10.00, suggesting a potential upside of 7.07%. Given Quotient’s higher possible upside, analysts clearly believe Quotient is more favorable than Akers Biosciences.
Earnings & Valuation
This table compares Akers Biosciences and Quotient’s top-line revenue, earnings per share and valuation.
Akers Biosciences has higher earnings, but lower revenue than Quotient.
Volatility and Risk
Akers Biosciences has a beta of -0.86, meaning that its share price is 186% less volatile than the S&P 500. Comparatively, Quotient has a beta of 1.31, meaning that its share price is 31% more volatile than the S&P 500.
This table compares Akers Biosciences and Quotient’s net margins, return on equity and return on assets.
Insider & Institutional Ownership
50.2% of Akers Biosciences shares are owned by institutional investors. Comparatively, 60.7% of Quotient shares are owned by institutional investors. 8.9% of Akers Biosciences shares are owned by company insiders. Comparatively, 17.4% of Quotient shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Quotient beats Akers Biosciences on 9 of the 11 factors compared between the two stocks.
About Akers Biosciences
Akers Biosciences, Inc., together with its subsidiaries, develops, manufactures, and supplies rapid screening and testing products designed to deliver healthcare information to healthcare providers and consumers in the United States, the People's Republic of China, and internationally. The company's marketed products include BreathScan, a disposable breath alcohol detector; BreathScan PRO, a quantitative breath alcohol detection system; METRON, a disposable breath ketone device to monitor ketosis; and BreathScan Lync, a non-invasive, quantitative measurement of biological markers for health and wellness. Its marketed products also include PIFA Heparin/PF4 and PIFA PLUSS PF4 rapid tests for Heparin/PF4 antibodies to detect an allergy to the used blood thinner, Heparin; seraSTAT, a rapid blood cell separator; Tri-Cholesterol Check', a rapid test for total and high density lipoprotein cholesterol and estimates low density lipo protein; and BreathScan OxiCHek, a breath test for oxidative stress using the Lync reader and digital app. The company's pipeline products comprise Breath Diabetic Ketoacidosis, a disposable breath ketone device for diabetic monitoring; Breath PulmoHealth Check', a suite of breath tests for biomarkers indicating asthma, chronic obstructive pulmonary disease, and lung cancer; PIFA PLUSS Chlamydia, a rapid test for sexually transmitted diseases; and BreathScan KetoChek, a breath test for ketosis using the Lync reader and digital app. Akers Biosciences, Inc. was founded in 1989 and is headquartered in Thorofare, New Jersey.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood-group antigens; reagent red blood cells, which enable the identification of blood-group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.